

Press release

May 2024

**MARIAN POPINIGIS AND BARTOSZ KRZESIAK APPOINTED TO THE SUPERVISORY BOARD  
OF BIORESEARCH PHARMA**

**ROBERT LITKA - CHIEF FINANCIAL OFFICER**

**The General Meeting of Shareholders of BioResearch Pharma S.A. (BRP), a company developing novel topical dermatological therapies based on repurposing, has appointed new members to its Supervisory Board. Joining BRP's Supervisory Board are: Marian Popinigis, a strategic investor in BioResearch Pharma S.A., a business angel, previously founder and CEO of BLIRT S.A., among others, and Bartosz Krzesiak, director of the equity issuance department at Navigator Capital Group.**

**Robert Litka joined the company, taking the position of Chief Financial Officer (CFO) of BioResearch Pharma S.A. Robert Litka was previously responsible for the finances of public companies (including BLIRT S.A., Mercor S.A.), M&A transactions. Recently, he served as CFO at QIAGEN Gdańsk sp. z o.o.**

Marian Popinigis, a seasonal entrepreneur and BRP strategic investor, was the founder and CEO of BLIRT S.A. - a biotechnology company that was sold in 2022 to the global corporation QIAGEN for PLN 250 million. He is also a co-founder of Mercor S.A. and previously served as its CEO for many years. Currently, as a business angel, he invests in biotech companies with growth potential.

**Bartosz Krzesiak**, advised on IPO, SPO, and listing of shares on the WSE regulated market and NewConnect. His previous experience includes Deutsche Bank in the Polish Strategic Corporates department and the Warsaw Stock Exchange. Member of supervisory boards and audit committees of companies listed on the regulated market of the WSE and on the NewConnect market. Member of the Council of Authorized Advisers (advisory committee of the WSE Management Board for the development of the alternative trading system). Business Centre Club expert on the capital market.

**Robert Litka** - CFO with international experience including the biotechnology industry. He supervised the finances of public companies, including Blirt S.A., Mercor S.A.. He started his financial career at the "Big Four", Deloitte and PricewaterhouseCoopers. He supervised the sale of Blirt S.A. QIAGEN Group (a PLN 250 million transaction), and at Mercor S.A. the sale of its fire door division to Assa Abloy for more than PLN 220 million. He also served as CFO at Assa Abloy Mercor Doors and CFO at QIAGEN Gdańsk sp. z o.o. He holds Statutory Auditor certification.

## **BRP's innovative dermatological therapies**

The company is developing two key products, BRP-011 and BRP-007, based on tested substances that have already demonstrated safety in humans. BRP-011 has the potential to become the first-in-class therapy for androgenetic alopecia. And BRP-007, with its unique mechanism of action may become an essential drug for topical application in psoriasis. Both BRP-011 and BRP-007 have been granted patents. The patent protection of BRP-011 covers the EU and the UK, while the BRP-007 patent covers the EU, the US and Australia.

---

### **About BRP:**

*BioResearch Pharma is a pharmaceutical company specializing in novel topical dermatological therapies. Repurposing of known, clinically tested medicinal substances is the foundation of BRP's business model, which is to enable faster commercialization—bringing effective and safe therapies to the market. The company is currently conducting projects to develop innovative drugs for topical treatment of androgenetic alopecia (BRP-011) and psoriasis (BRP-007).*

*The company was founded in 2021 by Łukasz Zybaczyński, a manager and physician with many years of experience in global pharmaceutical companies such as Eli Lilly, Merck & Co., and Merck KGaA; and Prof. Katarzyna Koziak from the Medical University of Warsaw, a biologist and the inventor of innovations being developed by BRP. The company's strategic investor is Marian Popinigis, co-founder and former CEO of the biotech company BLIRT S.A. (sold in 2022 to life sciences group Qiagen). Popinigis is also a co-founder of the exchange-listed Mercor S.A., and Ambient System sp. z o.o.*

[www.bioresearchpharma.com](http://www.bioresearchpharma.com)

### **For additional information please contact:**

Beata Cioczek | PR LAB

T: + 48 516 717 584

e-mail: [beata.cioczek@prlab.pl](mailto:beata.cioczek@prlab.pl)